Liver — guardian, modifier and target of sepsis
Key Points The liver represents a key integrator of microbial responses During microbial infection, the liver switches from tolerogenic towards immunogenic responses and initiates the production of acute-phase proteins Overwhelming inflammatory responses contribute to development of liver injury in...
Gespeichert in:
Veröffentlicht in: | Nature reviews. Gastroenterology & hepatology 2017-01, Vol.14 (1), p.55-66 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 66 |
---|---|
container_issue | 1 |
container_start_page | 55 |
container_title | Nature reviews. Gastroenterology & hepatology |
container_volume | 14 |
creator | Strnad, Pavel Tacke, Frank Koch, Alexander Trautwein, Christian |
description | Key Points
The liver represents a key integrator of microbial responses
During microbial infection, the liver switches from tolerogenic towards immunogenic responses and initiates the production of acute-phase proteins
Overwhelming inflammatory responses contribute to development of liver injury in sepsis and to progression of acute-on-chronic liver failure in patients with liver cirrhosis
Sepsis-induced liver injury comprises hypoxic hepatitis, sepsis-induced cholestasis and secondary sclerosing cholangitis of critically ill patients
Patients with liver cirrhosis have an increased risk of microbial infections and are at high risk of death from sepsis, therefore, a fast and risk-adjusted antimicrobial therapy is important
The liver regulates immune defence during sepsis, but is also a target for sepsis-related injury. Liver dysfunction can affect the prognosis of sepsis, particularly in patients with cirrhosis. In this Review, the importance of the liver in sepsis, the factors contributing to sepsis in patients with liver cirrhosis and new therapeutic strategies are discussed.
Sepsis and septic shock are characterized by life-threatening organ dysfunction caused by a dysregulated host response to infection. The liver has a central role during sepsis, and is essential to the regulation of immune defence during systemic infections by mechanisms such as bacterial clearance, acute-phase protein or cytokine production and metabolic adaptation to inflammation. However, the liver is also a target for sepsis-related injury, including hypoxic hepatitis due to ischaemia and shock, cholestasis due to altered bile metabolism, hepatocellular injury due to drug toxicity or overwhelming inflammation, as well as distinct pathologies such as secondary sclerosing cholangitis in critically ill patients. Hence, hepatic dysfunction substantially impairs the prognosis of sepsis and serves as a powerful independent predictor of mortality in the intensive care unit. Sepsis is particularly problematic in patients with liver cirrhosis (who experience increased bacterial translocation from the gut and impaired microbial defence) as it can trigger acute-on-chronic liver failure — a syndrome with high short-term mortality. Here, we review the importance of the liver as a guardian, modifier and target of sepsis, the factors that contribute to sepsis in patients with liver cirrhosis and new therapeutic strategies. |
doi_str_mv | 10.1038/nrgastro.2016.168 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_3143091209</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A474698409</galeid><sourcerecordid>A474698409</sourcerecordid><originalsourceid>FETCH-LOGICAL-c541t-9f5b0aa278594a1cc9a74578cfcd3c530060fed964e8f725b5b1d5a91c5551f73</originalsourceid><addsrcrecordid>eNp9kc1KxDAUhYMoOv48gBspCK6cMbfNbZvlIP7BgBtdh0ya1Mi0GZNWcOdD-IQ-idEZRwWVLBJuvnPuvRxC9oGOgGblSetrGTrvRimFfAR5uUYGUCAfIsVsffVmuEW2Q7inNEfM-CbZSgueMlrCgMDEPmqfvD6_JHUvfWVle5w0rrLGxrJsq6STvtZd4kwS9DzYsEs2jJwFvbe8d8jt-dnN6eVwcn1xdTqeDBUy6Ibc4JRKmRYlciZBKS4LhkWpjKoyhVkchhpd8Zzp0hQpTnEKFUoOChHBFNkOOVz4zr176HXoxL3rfRtbigxYRjmklP9HQYk5jwhPv6hazrSwrXGdl6qxQYkxK1jOS_bhNfqFiqfSjVWu1cbG-g_B0TfBnZaz7i64Wd9Z14afICxA5V0IXhsx97aR_kkAFe9Ris8oxXuUIkYZNQfLzfppo6uV4jO7CKQLIMSvttb-2-p_ur4Bs_uo-A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1856909392</pqid></control><display><type>article</type><title>Liver — guardian, modifier and target of sepsis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Strnad, Pavel ; Tacke, Frank ; Koch, Alexander ; Trautwein, Christian</creator><creatorcontrib>Strnad, Pavel ; Tacke, Frank ; Koch, Alexander ; Trautwein, Christian</creatorcontrib><description>Key Points
The liver represents a key integrator of microbial responses
During microbial infection, the liver switches from tolerogenic towards immunogenic responses and initiates the production of acute-phase proteins
Overwhelming inflammatory responses contribute to development of liver injury in sepsis and to progression of acute-on-chronic liver failure in patients with liver cirrhosis
Sepsis-induced liver injury comprises hypoxic hepatitis, sepsis-induced cholestasis and secondary sclerosing cholangitis of critically ill patients
Patients with liver cirrhosis have an increased risk of microbial infections and are at high risk of death from sepsis, therefore, a fast and risk-adjusted antimicrobial therapy is important
The liver regulates immune defence during sepsis, but is also a target for sepsis-related injury. Liver dysfunction can affect the prognosis of sepsis, particularly in patients with cirrhosis. In this Review, the importance of the liver in sepsis, the factors contributing to sepsis in patients with liver cirrhosis and new therapeutic strategies are discussed.
Sepsis and septic shock are characterized by life-threatening organ dysfunction caused by a dysregulated host response to infection. The liver has a central role during sepsis, and is essential to the regulation of immune defence during systemic infections by mechanisms such as bacterial clearance, acute-phase protein or cytokine production and metabolic adaptation to inflammation. However, the liver is also a target for sepsis-related injury, including hypoxic hepatitis due to ischaemia and shock, cholestasis due to altered bile metabolism, hepatocellular injury due to drug toxicity or overwhelming inflammation, as well as distinct pathologies such as secondary sclerosing cholangitis in critically ill patients. Hence, hepatic dysfunction substantially impairs the prognosis of sepsis and serves as a powerful independent predictor of mortality in the intensive care unit. Sepsis is particularly problematic in patients with liver cirrhosis (who experience increased bacterial translocation from the gut and impaired microbial defence) as it can trigger acute-on-chronic liver failure — a syndrome with high short-term mortality. Here, we review the importance of the liver as a guardian, modifier and target of sepsis, the factors that contribute to sepsis in patients with liver cirrhosis and new therapeutic strategies.</description><identifier>ISSN: 1759-5045</identifier><identifier>EISSN: 1759-5053</identifier><identifier>DOI: 10.1038/nrgastro.2016.168</identifier><identifier>PMID: 27924081</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/4020/2741/288 ; 692/4020/4021/1607/1604 ; 692/420/256/1980 ; 692/700/565 ; Acute phase proteins ; Acute-On-Chronic Liver Failure - etiology ; Anti-Bacterial Agents - therapeutic use ; Biomedicine ; Care and treatment ; Cholangitis ; Cholangitis, Sclerosing - etiology ; Cholestasis ; Cholestasis - etiology ; Chronic infection ; Cirrhosis ; Development and progression ; Gastroenterology ; Hepatitis ; Hepatology ; Humans ; Hypoxia ; Hypoxia - complications ; Immune response ; Immune system ; Immunogenicity ; Liver ; Liver - immunology ; Liver - injuries ; Liver cirrhosis ; Liver Cirrhosis - complications ; Liver diseases ; Medicine & Public Health ; Observations ; Physiological aspects ; review-article ; Sepsis ; Sepsis - complications ; Sepsis - drug therapy ; Sepsis - immunology</subject><ispartof>Nature reviews. Gastroenterology & hepatology, 2017-01, Vol.14 (1), p.55-66</ispartof><rights>Springer Nature Limited 2016</rights><rights>COPYRIGHT 2017 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jan 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c541t-9f5b0aa278594a1cc9a74578cfcd3c530060fed964e8f725b5b1d5a91c5551f73</citedby><cites>FETCH-LOGICAL-c541t-9f5b0aa278594a1cc9a74578cfcd3c530060fed964e8f725b5b1d5a91c5551f73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/nrgastro.2016.168$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/nrgastro.2016.168$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27924081$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Strnad, Pavel</creatorcontrib><creatorcontrib>Tacke, Frank</creatorcontrib><creatorcontrib>Koch, Alexander</creatorcontrib><creatorcontrib>Trautwein, Christian</creatorcontrib><title>Liver — guardian, modifier and target of sepsis</title><title>Nature reviews. Gastroenterology & hepatology</title><addtitle>Nat Rev Gastroenterol Hepatol</addtitle><addtitle>Nat Rev Gastroenterol Hepatol</addtitle><description>Key Points
The liver represents a key integrator of microbial responses
During microbial infection, the liver switches from tolerogenic towards immunogenic responses and initiates the production of acute-phase proteins
Overwhelming inflammatory responses contribute to development of liver injury in sepsis and to progression of acute-on-chronic liver failure in patients with liver cirrhosis
Sepsis-induced liver injury comprises hypoxic hepatitis, sepsis-induced cholestasis and secondary sclerosing cholangitis of critically ill patients
Patients with liver cirrhosis have an increased risk of microbial infections and are at high risk of death from sepsis, therefore, a fast and risk-adjusted antimicrobial therapy is important
The liver regulates immune defence during sepsis, but is also a target for sepsis-related injury. Liver dysfunction can affect the prognosis of sepsis, particularly in patients with cirrhosis. In this Review, the importance of the liver in sepsis, the factors contributing to sepsis in patients with liver cirrhosis and new therapeutic strategies are discussed.
Sepsis and septic shock are characterized by life-threatening organ dysfunction caused by a dysregulated host response to infection. The liver has a central role during sepsis, and is essential to the regulation of immune defence during systemic infections by mechanisms such as bacterial clearance, acute-phase protein or cytokine production and metabolic adaptation to inflammation. However, the liver is also a target for sepsis-related injury, including hypoxic hepatitis due to ischaemia and shock, cholestasis due to altered bile metabolism, hepatocellular injury due to drug toxicity or overwhelming inflammation, as well as distinct pathologies such as secondary sclerosing cholangitis in critically ill patients. Hence, hepatic dysfunction substantially impairs the prognosis of sepsis and serves as a powerful independent predictor of mortality in the intensive care unit. Sepsis is particularly problematic in patients with liver cirrhosis (who experience increased bacterial translocation from the gut and impaired microbial defence) as it can trigger acute-on-chronic liver failure — a syndrome with high short-term mortality. Here, we review the importance of the liver as a guardian, modifier and target of sepsis, the factors that contribute to sepsis in patients with liver cirrhosis and new therapeutic strategies.</description><subject>692/4020/2741/288</subject><subject>692/4020/4021/1607/1604</subject><subject>692/420/256/1980</subject><subject>692/700/565</subject><subject>Acute phase proteins</subject><subject>Acute-On-Chronic Liver Failure - etiology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Biomedicine</subject><subject>Care and treatment</subject><subject>Cholangitis</subject><subject>Cholangitis, Sclerosing - etiology</subject><subject>Cholestasis</subject><subject>Cholestasis - etiology</subject><subject>Chronic infection</subject><subject>Cirrhosis</subject><subject>Development and progression</subject><subject>Gastroenterology</subject><subject>Hepatitis</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Hypoxia</subject><subject>Hypoxia - complications</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Immunogenicity</subject><subject>Liver</subject><subject>Liver - immunology</subject><subject>Liver - injuries</subject><subject>Liver cirrhosis</subject><subject>Liver Cirrhosis - complications</subject><subject>Liver diseases</subject><subject>Medicine & Public Health</subject><subject>Observations</subject><subject>Physiological aspects</subject><subject>review-article</subject><subject>Sepsis</subject><subject>Sepsis - complications</subject><subject>Sepsis - drug therapy</subject><subject>Sepsis - immunology</subject><issn>1759-5045</issn><issn>1759-5053</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kc1KxDAUhYMoOv48gBspCK6cMbfNbZvlIP7BgBtdh0ya1Mi0GZNWcOdD-IQ-idEZRwWVLBJuvnPuvRxC9oGOgGblSetrGTrvRimFfAR5uUYGUCAfIsVsffVmuEW2Q7inNEfM-CbZSgueMlrCgMDEPmqfvD6_JHUvfWVle5w0rrLGxrJsq6STvtZd4kwS9DzYsEs2jJwFvbe8d8jt-dnN6eVwcn1xdTqeDBUy6Ibc4JRKmRYlciZBKS4LhkWpjKoyhVkchhpd8Zzp0hQpTnEKFUoOChHBFNkOOVz4zr176HXoxL3rfRtbigxYRjmklP9HQYk5jwhPv6hazrSwrXGdl6qxQYkxK1jOS_bhNfqFiqfSjVWu1cbG-g_B0TfBnZaz7i64Wd9Z14afICxA5V0IXhsx97aR_kkAFe9Ris8oxXuUIkYZNQfLzfppo6uV4jO7CKQLIMSvttb-2-p_ur4Bs_uo-A</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Strnad, Pavel</creator><creator>Tacke, Frank</creator><creator>Koch, Alexander</creator><creator>Trautwein, Christian</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20170101</creationdate><title>Liver — guardian, modifier and target of sepsis</title><author>Strnad, Pavel ; Tacke, Frank ; Koch, Alexander ; Trautwein, Christian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c541t-9f5b0aa278594a1cc9a74578cfcd3c530060fed964e8f725b5b1d5a91c5551f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>692/4020/2741/288</topic><topic>692/4020/4021/1607/1604</topic><topic>692/420/256/1980</topic><topic>692/700/565</topic><topic>Acute phase proteins</topic><topic>Acute-On-Chronic Liver Failure - etiology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Biomedicine</topic><topic>Care and treatment</topic><topic>Cholangitis</topic><topic>Cholangitis, Sclerosing - etiology</topic><topic>Cholestasis</topic><topic>Cholestasis - etiology</topic><topic>Chronic infection</topic><topic>Cirrhosis</topic><topic>Development and progression</topic><topic>Gastroenterology</topic><topic>Hepatitis</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Hypoxia</topic><topic>Hypoxia - complications</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Immunogenicity</topic><topic>Liver</topic><topic>Liver - immunology</topic><topic>Liver - injuries</topic><topic>Liver cirrhosis</topic><topic>Liver Cirrhosis - complications</topic><topic>Liver diseases</topic><topic>Medicine & Public Health</topic><topic>Observations</topic><topic>Physiological aspects</topic><topic>review-article</topic><topic>Sepsis</topic><topic>Sepsis - complications</topic><topic>Sepsis - drug therapy</topic><topic>Sepsis - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Strnad, Pavel</creatorcontrib><creatorcontrib>Tacke, Frank</creatorcontrib><creatorcontrib>Koch, Alexander</creatorcontrib><creatorcontrib>Trautwein, Christian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Nature reviews. Gastroenterology & hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Strnad, Pavel</au><au>Tacke, Frank</au><au>Koch, Alexander</au><au>Trautwein, Christian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Liver — guardian, modifier and target of sepsis</atitle><jtitle>Nature reviews. Gastroenterology & hepatology</jtitle><stitle>Nat Rev Gastroenterol Hepatol</stitle><addtitle>Nat Rev Gastroenterol Hepatol</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>14</volume><issue>1</issue><spage>55</spage><epage>66</epage><pages>55-66</pages><issn>1759-5045</issn><eissn>1759-5053</eissn><abstract>Key Points
The liver represents a key integrator of microbial responses
During microbial infection, the liver switches from tolerogenic towards immunogenic responses and initiates the production of acute-phase proteins
Overwhelming inflammatory responses contribute to development of liver injury in sepsis and to progression of acute-on-chronic liver failure in patients with liver cirrhosis
Sepsis-induced liver injury comprises hypoxic hepatitis, sepsis-induced cholestasis and secondary sclerosing cholangitis of critically ill patients
Patients with liver cirrhosis have an increased risk of microbial infections and are at high risk of death from sepsis, therefore, a fast and risk-adjusted antimicrobial therapy is important
The liver regulates immune defence during sepsis, but is also a target for sepsis-related injury. Liver dysfunction can affect the prognosis of sepsis, particularly in patients with cirrhosis. In this Review, the importance of the liver in sepsis, the factors contributing to sepsis in patients with liver cirrhosis and new therapeutic strategies are discussed.
Sepsis and septic shock are characterized by life-threatening organ dysfunction caused by a dysregulated host response to infection. The liver has a central role during sepsis, and is essential to the regulation of immune defence during systemic infections by mechanisms such as bacterial clearance, acute-phase protein or cytokine production and metabolic adaptation to inflammation. However, the liver is also a target for sepsis-related injury, including hypoxic hepatitis due to ischaemia and shock, cholestasis due to altered bile metabolism, hepatocellular injury due to drug toxicity or overwhelming inflammation, as well as distinct pathologies such as secondary sclerosing cholangitis in critically ill patients. Hence, hepatic dysfunction substantially impairs the prognosis of sepsis and serves as a powerful independent predictor of mortality in the intensive care unit. Sepsis is particularly problematic in patients with liver cirrhosis (who experience increased bacterial translocation from the gut and impaired microbial defence) as it can trigger acute-on-chronic liver failure — a syndrome with high short-term mortality. Here, we review the importance of the liver as a guardian, modifier and target of sepsis, the factors that contribute to sepsis in patients with liver cirrhosis and new therapeutic strategies.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>27924081</pmid><doi>10.1038/nrgastro.2016.168</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1759-5045 |
ispartof | Nature reviews. Gastroenterology & hepatology, 2017-01, Vol.14 (1), p.55-66 |
issn | 1759-5045 1759-5053 |
language | eng |
recordid | cdi_proquest_journals_3143091209 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | 692/4020/2741/288 692/4020/4021/1607/1604 692/420/256/1980 692/700/565 Acute phase proteins Acute-On-Chronic Liver Failure - etiology Anti-Bacterial Agents - therapeutic use Biomedicine Care and treatment Cholangitis Cholangitis, Sclerosing - etiology Cholestasis Cholestasis - etiology Chronic infection Cirrhosis Development and progression Gastroenterology Hepatitis Hepatology Humans Hypoxia Hypoxia - complications Immune response Immune system Immunogenicity Liver Liver - immunology Liver - injuries Liver cirrhosis Liver Cirrhosis - complications Liver diseases Medicine & Public Health Observations Physiological aspects review-article Sepsis Sepsis - complications Sepsis - drug therapy Sepsis - immunology |
title | Liver — guardian, modifier and target of sepsis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T09%3A33%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Liver%20%E2%80%94%20guardian,%20modifier%20and%20target%20of%20sepsis&rft.jtitle=Nature%20reviews.%20Gastroenterology%20&%20hepatology&rft.au=Strnad,%20Pavel&rft.date=2017-01-01&rft.volume=14&rft.issue=1&rft.spage=55&rft.epage=66&rft.pages=55-66&rft.issn=1759-5045&rft.eissn=1759-5053&rft_id=info:doi/10.1038/nrgastro.2016.168&rft_dat=%3Cgale_proqu%3EA474698409%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1856909392&rft_id=info:pmid/27924081&rft_galeid=A474698409&rfr_iscdi=true |